DBIBB
- Product Name
- DBIBB
- CAS No.
- 1569309-92-7
- Chemical Name
- DBIBB
- Synonyms
- DBIBB;DBIBB, 10 mM in DMSO;Benzoic acid, 2-[[[4-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)butyl]amino]sulfonyl]-
- CBNumber
- CB33152600
- Molecular Formula
- C23H20N2O6S
- Formula Weight
- 452.48
- MOL File
- 1569309-92-7.mol
DBIBB Property
- Boiling point:
- 710.4±70.0 °C(Predicted)
- Density
- 1.437±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- ≤30mg/ml in DMSO;10mg/ml in dimethyl formamide
- form
- crystalline solid
- pka
- 3.02±0.36(Predicted)
- color
- Off-white to light brown
N-Bromosuccinimide Price
- Product number
- 17529
- Product name
- DBIBB
- Purity
- ≥98%
- Packaging
- 1mg
- Price
- $57
- Updated
- 2024/03/01
- Product number
- 17529
- Product name
- DBIBB
- Purity
- ≥98%
- Packaging
- 5mg
- Price
- $220
- Updated
- 2024/03/01
- Product number
- 17529
- Product name
- DBIBB
- Purity
- ≥98%
- Packaging
- 10mg
- Price
- $302
- Updated
- 2024/03/01
- Product number
- 445823
- Product name
- DBIBB
- Packaging
- 1mg
- Price
- $319
- Updated
- 2021/12/16
- Product number
- D194975
- Product name
- DBIBB
- Packaging
- 10mg
- Price
- $265
- Updated
- 2021/12/16
DBIBB Chemical Properties,Usage,Production
Uses
DBIBB is a non-lipid agonist of LPA2 (lysophosphatidic acid receptor 2), protecting rat intestinal crpyt epithelium-like IEC-6 cells against caspase 3/7 activation and apoptosis.
Biological Activity
dbibb, a butylsulfamoyl benzoic acid analog, is a non-lipid agonist of lpa2 with an ec50 of 0.10 μm. dbibb has no effect at other lpa receptor subtypes [1]. the bioactive phospholipid lysophosphatidic acid (lpa) has been involved in stimulating cell proliferation, migration and survival by acting on its cognate g-protein-coupled receptors. aberrant lpa production, receptor expression and signalling probably contribute to cancer initiation, progression and metastasis [2].
in vitro
dbibb treatment postirradiation significantly (p< 0.01) increased the clonogenic survival of iec-6 cells in the 2-6 gy dose range. dbibb reduced dna fragmentation 4hr after irradiation in a dose dependent manner. dbibb also reduced caspase 3/7 activity and dna fragmentation in lpa2mef treated with adriamycin. in purified cd34+ progenitor cells, dbibb significantly increased the total number of colonies and specifically enhanced the survival of the granulocyte/macrophage lineages [1].
in vivo
using a murine gi-ars mice model of partial-body irradiation (pbi) with shielding of the bone marrow contained in the tibiae, fibulae, and paws, administrations of up to 10 mg/kg of dbibb for 10 days showed no visually observable adverse effects and pathological findings at necropsy, indicating the lack of toxicity. the group that received 10 mg/kg dbibb showed a significant increase in survival. in c57bl/6 mice, dbibb showed a dose-dependent increase in the number of surviving crypts compared with the vehicle control [1].
References
[1] patil r, szabó e, fells j i, et al. combined mitigation of the gastrointestinal and hematopoietic acute radiation syndromes by an lpa 2 receptor-specific nonlipid agonist[j]. chemistry & biology, 2015, 22(2): 206-216.
[2] mills g b, moolenaar w h. the emerging role of lysophosphatidic acid in cancer[j]. nature reviews cancer, 2003, 3(8): 582-591.
DBIBB Preparation Products And Raw materials
Raw materials
Preparation Products
DBIBB Suppliers
- Tel
- +1-781-999-5354 +1-00000000000
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32161
- Advantage
- 58
- Tel
- --
- Fax
- --
- sales@apexbt.com
- Country
- United States
- ProdList
- 6251
- Advantage
- 58
- Tel
- --
- Fax
- --
- cayman@caymanchem.com
- Country
- United States
- ProdList
- 6213
- Advantage
- 81